Role of microbial-modulated bile acid receptor signaling in breast cancer
微生物调节胆汁酸受体信号传导在乳腺癌中的作用
基本信息
- 批准号:10053592
- 负责人:
- 金额:$ 41.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:7alpha hydroxylaseAblationAddressAdjuvantAffectAggressive behaviorAgonistAntibioticsBile AcidsBlood CirculationBody Weight decreasedBreastBreast Cancer CellBreast Cancer ModelBreast Cancer PatientCell CommunicationCellsClinicalDataDietary InterventionEnterohepatic CirculationEstrogen ReceptorsGenerationsGeneticGoalsGrowthHumanHydroxylationImmuneImmune checkpoint inhibitorImmunologic SurveillanceImmunosuppressionImmunotherapeutic agentImmunotherapyImplantIn VitroIncidenceIntestinal NeoplasmsIntestinesKnowledgeLinkLiverMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMediator of activation proteinMetabolicMicrobeModelingModificationMusNeoplasm MetastasisObesityOutcomePathologicPathway interactionsPatient-Focused OutcomesPatientsPharmacologyPhysiologicalPlayPrimary carcinoma of the liver cellsRaceReceptor SignalingRelapseReportingRoleSamplingSecondary toShapesSignal TransductionStromal CellsTestingTherapeuticTimeTissuesTreatment EfficacyTumor ImmunityTumor MarkersTumor SubtypeTumor stageWeightWorkbacterial metabolismbariatric surgerybreast cancer progressioncancer cellcancer immunotherapycancer subtypescarcinogenicitychemotherapycommensal microbesexperimental studyfecal transplantationgain of functiongut microbiomegut microbiotahost microbiotaimprovedinnovationmalignant breast neoplasmmicrobialmicrobial communitymicrobiomemicrobiome alterationmicrobiome researchmicrobiotamigrationmimeticsnonhuman primatenovelnovel therapeuticspersonalized medicineprecision medicinereceptorreceptor expressionresponsesmall moleculetargeted treatmenttherapeutic evaluationtriple-negative invasive breast carcinomatumortumor microenvironmenttumor progressiontumor-immune system interactions
项目摘要
SUMMARY
Anti-tumor immunity varies due to interactions between innate and adaptive immune cells, microbial
community diversity, host and microbially derived metabolites, and other local factors that shape tumoricidal
responses. While most of the recent microbiome research focuses on the gut microbiome and cancer
outcomes, extra-intestinal microbial communities are detected in the tumor microenvironment (TME). We
recently reported that specific microbes identified in patient breast tumors compared to pathologically normal
breast samples associated with tumor stage, tumor subtype, and for the first time, race. Triple Negative Breast
Cancer (TNBC), an aggressive subtype that has generally eluded personalized medicine approaches,
contained unique microbes that may mediate immunosuppression and impact standard chemotherapy or
immune checkpoint inhibitor (ICI) efficacies. Yet to date, mechanisms underpinning these observations are
unresolved as to how the gut and/or extra-intestinal microbiome influence BC onset, progression, and
response to therapies, which is a major knowledge gap in this field. One cogent mechanism that may link
microbes to anti-tumor immunity are microbially modified metabolites, namely bile acids. Certain microbes rich
in 7-alpha-hydroxylase convert primary to secondary bile acids which regulate bile acid composition. Bile acids
have been shown to limit progression and metastasis in other cancers through reversing immunosuppression,
but minimal work has explored the role of bile acids in BC. Bile acids signal through several bile acid receptors
including farnesoid X receptor (FXR). We posit that specific gut or local resident microbes that impact bile acid
pools and composition will interact with cells expressing FXR to regulate the TME immune milieu. We report for
the first time that patients with high FXR expression have greater relapse-free survival uniquely in TNBC
subtype, but not in less aggressive luminal BC subtype, suggesting potential for targeted approaches. The
overall objective of this proposal is to test mechanisms linking MicrobesBile AcidsTNBC which poses an
opportunity to generate novel therapeutics and precision medicine informed by microbial compositions. Our
innovative approach interrogates targetable microbial pathways that we demonstrate change the microbiome,
bile acids, and tumor progression. Our central hypothesis is microbial composition and microbially-modified
metabolic products, such as bile acids, increase immunotherapeutic efficacy through reprogramming the TME
leading to enhanced anti-tumor immunity. We will test our hypothesis by performing the following aims: 1)
Determine if commensal microbes play a physiological role in TNBC anti-tumor immunity; 2) Determine if the
microbiome alters immunosurveillance of early tumor onset and progression; 3) Determine if pharmacologic
bile acid receptor agonism improves TNBC immunotherapy. Findings generated will have high impact because
the lack of targeted therapies for TNBC presents a great unmet clinical need and could be transformative to
improve patient outcomes.
概括
抗肿瘤免疫因先天免疫细胞和适应性免疫细胞、微生物之间的相互作用而变化
群落多样性、宿主和微生物衍生的代谢物以及其他影响肿瘤杀灭作用的局部因素
回应。虽然最近大多数微生物组研究都集中在肠道微生物组和癌症上
结果,在肿瘤微环境(TME)中检测到肠外微生物群落。我们
最近报道,与病理正常的患者相比,在患者乳腺肿瘤中发现了特定的微生物
乳房样本与肿瘤分期、肿瘤亚型相关,并且首次与种族相关。三阴性乳房
癌症 (TNBC) 是一种侵袭性亚型,通常无法采用个性化医疗方法,
含有独特的微生物,可能介导免疫抑制并影响标准化疗或
免疫检查点抑制剂(ICI)的功效。然而迄今为止,支撑这些观察结果的机制是
肠道和/或肠外微生物组如何影响 BC 的发病、进展和影响尚未解决
对治疗的反应,这是该领域的一个主要知识差距。一种可能联系起来的令人信服的机制
微生物发挥抗肿瘤免疫作用的是微生物修饰的代谢产物,即胆汁酸。富含某些微生物
7-α-羟化酶将初级胆汁酸转化为次级胆汁酸,从而调节胆汁酸的组成。胆汁酸
已被证明可以通过逆转免疫抑制来限制其他癌症的进展和转移,
但探索胆汁酸在 BC 中的作用的工作却很少。胆汁酸通过几种胆汁酸受体发出信号
包括法尼醇X受体(FXR)。我们假设影响胆汁酸的特定肠道或当地常驻微生物
池和组合物将与表达 FXR 的细胞相互作用以调节 TME 免疫环境。我们报道的是
FXR 高表达的患者首次在 TNBC 中具有更高的无复发生存率
亚型,但不是侵袭性较低的管腔 BC 亚型,这表明有针对性的方法的潜力。这
该提案的总体目标是测试微生物胆汁酸TNBC 之间的联系机制,这构成了
通过微生物组合物产生新疗法和精准医学的机会。我们的
创新方法询问我们证明可以改变微生物组的目标微生物途径,
胆汁酸和肿瘤进展。我们的中心假设是微生物组成和微生物修饰
代谢产物,例如胆汁酸,通过重新编程 TME 提高免疫治疗功效
从而增强抗肿瘤免疫力。我们将通过执行以下目标来检验我们的假设:1)
确定共生微生物是否在 TNBC 抗肿瘤免疫中发挥生理作用; 2) 确定是否
微生物组改变早期肿瘤发病和进展的免疫监视; 3) 确定是否具有药理作用
胆汁酸受体激动可改善 TNBC 免疫治疗。所产生的调查结果将产生重大影响,因为
TNBC 缺乏靶向治疗存在巨大的未满足的临床需求,并且可能会带来变革
改善患者的治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Liza Makowski-Hayes其他文献
Liza Makowski-Hayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Liza Makowski-Hayes', 18)}}的其他基金
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
使用新型临床前模型确定三阴性乳腺癌的易感位点
- 批准号:
10573287 - 财政年份:2022
- 资助金额:
$ 41.73万 - 项目类别:
Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.
确定微生物衍生的代谢物对肥胖驱动的癌症风险中的保护性免疫的贡献。
- 批准号:
10505372 - 财政年份:2022
- 资助金额:
$ 41.73万 - 项目类别:
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model
使用新型临床前模型确定三阴性乳腺癌的易感位点
- 批准号:
10444546 - 财政年份:2022
- 资助金额:
$ 41.73万 - 项目类别:
Role of microbial-modulated bile acid receptor signaling in breast cancer
微生物调节胆汁酸受体信号传导在乳腺癌中的作用
- 批准号:
10404525 - 财政年份:2020
- 资助金额:
$ 41.73万 - 项目类别:
Role of microbial-modulated bile acid receptor signaling in breast cancer
微生物调节胆汁酸受体信号传导在乳腺癌中的作用
- 批准号:
10219210 - 财政年份:2020
- 资助金额:
$ 41.73万 - 项目类别:
Role of microbial-modulated bile acid receptor signaling in breast cancer
微生物调节胆汁酸受体信号传导在乳腺癌中的作用
- 批准号:
10614037 - 财政年份:2020
- 资助金额:
$ 41.73万 - 项目类别:
(PQA2) Reversing Carcinogenic Effect of Obesity on Basal-like Breast Cancer
(PQA2) 逆转肥胖对基底样乳腺癌的致癌作用
- 批准号:
8590946 - 财政年份:2013
- 资助金额:
$ 41.73万 - 项目类别:
Macrophage Mitochondrial Stress in Inflammation, Insulin Resistance & Obesity
炎症、胰岛素抵抗中的巨噬细胞线粒体应激
- 批准号:
8208231 - 财政年份:2007
- 资助金额:
$ 41.73万 - 项目类别:
Macrophage Mitochondrial Stress in Inflammation, Insulin Resistance & Obesity
炎症、胰岛素抵抗中的巨噬细胞线粒体应激
- 批准号:
8121191 - 财政年份:2007
- 资助金额:
$ 41.73万 - 项目类别:
Macrophage Mitochondrial Stress in Inflammation, Insulin Resistance & Obesity
炎症、胰岛素抵抗中的巨噬细胞线粒体应激
- 批准号:
7479191 - 财政年份:2007
- 资助金额:
$ 41.73万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 41.73万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 41.73万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 41.73万 - 项目类别:
Standard Grant














{{item.name}}会员




